Insider Trading July 10, 2026 06:27 PM

Seer Director Dipchand Executes $23,265 Stock Sale Amid Strategic Developments

Director Nishar Dipchand's recent sale of 10,660 shares follows a 34% weekly surge and precedes a $2.45 per share buyout proposal from CEO Omid Farokhzad.

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
SEER

Seer, Inc. (NASDAQ:SEER) director Nishar Dipchand sold 10,660 shares of the company's Class A Common Stock on July 8, 2026, generating approximately $23,265. The transaction, executed under a Rule 10b5-1 trading plan adopted on August 8, 2025, was intended to cover tax liabilities from restricted stock unit vesting. The sale occurred as SEER stock traded near its 52-week high of $2.41, following a 34% weekly increase. According to InvestingPro analysis, the stock trades below its estimated fair value of $3.10. Recent corporate activities include a $2.45 per share cash buyout proposal from Chair and CEO Omid Farokhzad, accompanied by two contingent value rights. Canaccord Genuity maintained a Buy rating with a $4.00 price target. Seer also filed an investor presentation with the SEC for its upcoming annual stockholder meeting, received European Patent Office support for its proteomics technology patent, and saw the International Trade Commission investigate Nanomics over patent disputes.

Seer Director Dipchand Executes $23,265 Stock Sale Amid Strategic Developments
SEER
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Seer director Nishar Dipchand sold 10,660 shares for $23,265 under a pre-existing Rule 10b5-1 plan to cover tax liabilities from restricted stock unit vesting.
  • The stock traded near a 52-week high of $2.41 after a 34% weekly surge, while InvestingPro analysis suggests the stock is undervalued with a fair value of $3.10.
  • CEO Omid Farokhzad proposed a $2.45 per share cash buyout with contingent value rights, coinciding with a SEC filing and patent developments in the proteomics sector.

Nishar Dipchand, a director at Seer, Inc. (NASDAQ:SEER), completed the sale of 10,660 shares of the company's Class A Common Stock on July 8, 2026. The transaction yielded approximately $23,265, with the shares sold at prices ranging from $2.17 to $2.22 each. This execution occurred as the stock approached its 52-week high of $2.41, marking a period of significant momentum following a 34% surge over the previous week.

The shares were divested at a weighted average price of $2.1825 per share. The sale was conducted in accordance with a Rule 10b5-1 trading plan that Mr. Dipchand established on August 8, 2025. This specific plan was designed to address tax obligations resulting from the vesting and settlement of restricted stock units. Following the completion of these transactions, Mr. Dipchand retained direct ownership of 59,044 shares of Seer's Class A Common Stock.

In parallel corporate developments, Seer Inc. disclosed a buyout proposal initiated by its Chair and CEO, Omid Farokhzad. The offer structures $2.45 per share in cash alongside two contingent value rights that may deliver additional value to shareholders. This proposal aligns with recent analyst activity, as Canaccord Genuity reiterated a Buy rating for Seer, maintaining a $4.00 price target.

Further strategic disclosures include an investor presentation filed with the U.S. Securities and Exchange Commission, which outlines the company's strategic progress and future opportunities in preparation for its upcoming annual stockholder meeting. On the intellectual property front, the European Patent Office upheld Seer's patent related to proteomics technology despite opposition. Additionally, the International Trade Commission has initiated an investigation into Nanomics concerning Seer's patents, highlighting ongoing legal and strategic activity surrounding the company.

Risks

  • The stock price volatility, evidenced by a 34% weekly surge and subsequent trading near highs, introduces short-term pricing uncertainty for investors.
  • The contingent value rights attached to the buyout proposal add complexity and potential variability to the total consideration shareholders may receive.
  • The International Trade Commission investigation into Nanomics introduces legal and regulatory uncertainty that could impact the proteomics technology market.

More from Insider Trading

Mineralys Therapeutics CMO Rodman Executes Pre-Arranged Stock Sale and Option Exercise Jul 10, 2026 Taysha Gene Therapies President Executes $1.25 Million Share Sale Under Pre-Approved Plan Jul 10, 2026 Broadcom Director Gayla Delly Disposes of $728,000 in AVGO Shares Amidst Strategic Expansion Jul 10, 2026 Broadcom Legal Officer Executes Nearly $9.5 Million Stock Sale Jul 10, 2026 Thrivent Financial Reduces Position in Gloo Holdings Amid Market Volatility Jul 10, 2026